Slide 1: Bionano Investor Presentation
September 14, 2026 Albert Luderer, PhD Chairman and Interim CEO Bionano
Slide 2: Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results
Slide 3: Bionano Has Digitized the Human Chromosome
Optical genome mapping (OGM) a genomic analysis technique that is: Transitioning into the clinic and transforming structural variant analysis Obsoleting major laboratory standards of chromosomal analysis Consistently identifying previously undetected clinically relevant chromosomal structural varian
Slide 4: OGM is Gaining Reimbursement Traction and Expanding
OGM is Gaining Reimbursement Traction and Expanding c c c c Coding Milestone The American Medical Association has established two (2) unique CPT codes for OGM analysis – one for hematologic malignancies and another for constitutional genetics with both for routine use as clinical laboratory procedur
Slide 5: Four Decades of Diagnostics Disruption
Four Decades of Diagnostics Disruption 1990s Manual ISH Automated ISH 2000s Agar Culture PCR GENEOHM SCIENCES 2010s Sanger Sequencing NGS 2020s Cytogenetics Digital Pathology Each decade has brought one category-defining technology conversion in clinical laboratory practice — led by a single company
Slide 6: Digital Pathology is an Emerging Mega Trend in Laboratory Practice
Digital Pathology is an Emerging “Mega Trend” in Laboratory Practice Cytogenetics Molecular Anatomic Pathology/Clinical Pathology Karyotyping FISH CMA RNA (Transcriptomics) DNA (Sequencing) Flow cytometry/Mass spectrometry Analog Fusion profiling Transcript Panels (hotspot/actionable) Whole genome I
Slide 7: OGM Replaces Traditional Cyto Tools & Bridges the Sequencing Coverage Gap
Short-read c Medical Society Recommendations Ionic (NA from FFPE) Sequencing Cytogenetics SNVs InDels Structural Variants (SVs) 5 Mbp 500 bp 1 bp 500 kbp 50 kbp 5 kbp 1kbp Whole Chromosome Karyotyping Array (gains and losses only) FISH (targeted) Long-read Coverage Gap OGM SVs in this size range wer
Slide 8: Traditional Methods for Structural Variant Detection are Outdated
Traditional Methods for Structural Variant Detection are Outdated and Leave a Significant Number of Questions Unanswered Karyotyping FISH (fluorescence in-situ hybridization) Microarrays Traditional cytogenetics requires multiple methods that are labor intense, time-consuming, repetitive & costly. U
Slide 9: OGM Uses Nanochannel Arrays to Linearize Ultra-High Molecular Weight DNA
OGM Uses Nanochannel Arrays to Linearize Ultra-High Molecular Weight DNA molecule flow Reservoir Lip Pillar region NanoChannels
Slide 10: High-Resolution Digital Karyotyping
High-Resolution Digital Karyotyping Traditional Cytogenetics 1 band = 5mb OGM Linearized High Molecular Weight DNA Yields a High-Resolution Digital Karyotyping 10,000 RESOLUTION OGM PROVIDES ~1,000x times more “bands” IN THE FORM OF LABELS AND CAN DETECT CHROMOSOMAL ABERRATIONS AS SMALL AS 500BP
Slide 11: Bionano Provides an End-to-End Solution for OGM
DNA Isolation Kits Genome Imaging Chips Genome Imaging Instruments High-performance Compute Servers Variant Calling Algorithms & Pipelines Visualization, Interpretation & Reporting Software DNA Labeling Kits Automated DNA Isolation System For OGM 8 Bionano Provides an End-to-End Solution for OGM Ion
Slide 12: OGM Validation is Extensive with Thousands of Published Genomes
117 new publications in Q2 2026 across a range of applications 1,335 human clinical research genomes published in Q2 2026 reaching 16,000+ in total ~500 before 2021 + ~1,100 in 2021 + ~1,500 in 2022 + ~2,000 in 2023 + ~2,800 in 2024 + ~4,500 in 2025 New Publication CAGR (2020-2025): 28% Published Ge
Slide 13: Focus on Transforming Cytogenetics to Serve Three Key Application Areas
Focus on Transforming Cytogenetics to Serve Three Key Application Areas https://www.nature.com/articles/s41375-022-01652-8#Abs1 https://www.embopress.org/doi/epdf/10.15252/embj.2023114188 OGM prognostic scores were different for 17 to 21% of study subjects OGM revealed additional pathogenic variants
Slide 14: Routine Customers Account for ~83% of Consumables Revenues
Company-Wide Baseline All installed sites & systems, all customer types 321 Global OGM Sites 387 Global Installed OGM Systems $44K Avg. Consumables Revenue / Site Routine Use Customer Segmentation Read top to bottom: customer count → share of FY25 consumables revenue → revenue per site 14 Routine Cu
Slide 15: Financial Transformation: FY2023–FY2025
Financial Transformation: FY2023–FY2025 Focused on the 25% of customers representing 75% of sales De-emphasized instrument sales and focused on flowcell utilization Relied on sufficient installed base to drive utilization Emphasized routine use Eliminated nonessential business Discontinued legacy Li
Slide 16: Financial Transformation: FY2023–FY2025 Metrics
Non-GAAP OPEX Trend ($M, Quarterly) Adjusted Core Gross Margin Trend Financial Transformation: FY2023–FY2025 -71% Non-GAAP OPEX FY23 → FY25 ($126.6M → $36.6M) +25 pts Adj. Core Gross Margin FY23 avg 22% → FY25 avg 47% $28.5M FY25 Core Revenue (ex. discontinued clinical services) -84% Adjusted EBITDA
Slide 17: Q2 2026 Operating KPIs
Q2 2026 Operating KPIs Revenue Beat & Raise – Actuals of $8.2M > Q2 guidance of $7.5 - $7.8M; Raised lower end of annual guidance from $30 - $33M to $31 - $33M Record Highs – Flow cells sold and Gross Margin JGB Debt retired – Was secured by restricted cash of $10.3 FY ‘26 Guidance $31 – 33M Q2 KPI
Slide 18: FY27 Outlook – Projecting 56% Year-over-Year Growth
FY27 Outlook – Projecting 56% Year-over-Year Growth $50-54 M FY27 Total Revenue 48-55 New Instrument Placements ~$0 Adj. EBITDA Exit Rate (Q4 FY27) The estimates on this page were derived by the midpoint of management’s outlook based on historical performance and expected growth trends. There are se
Slide 19: Long Range Plan: FY26–FY29 Outlook
Long Range Plan: FY26–FY29 Outlook FY26–FY29 Estimated Financial Summary Estimated Revenue Build by Segment ($M) Estimated EBITDA Trajectory ($M) FY26 FY27 FY28 FY29 Total Revenue Range – GAAP 31 - 33 50 - 54 70 - 75 101 -108 Growth % 19% 56% 42% 39% GM% - GAAP 49% 53% 56% 58% OPEX – GAAP 45.8 46.3
Slide 20: AMA CPT Code for OGM
AMA CPT Code for OGM in Hematologic Malignancies Current Code #: 81195 Final payment determination effective Jan 1, 2026: $1,853.22 47% price increase in 2026 Market Opportunity Test: OGM Hematologic Malignancies Application pending with National Authorities Insurance Coverage Test: OGM Hematologic
Slide 21: Local Coverage Determination from MolDX
Local Coverage Determination from MolDX MolDX states include 61% of the population of the United States MolDX Not MolDX MolDX has written and published a local coverage determination for OGM in hematologic malignancies for public comment. Following public comment, it is expected to be published and
Slide 22: New York State Approval Unlocks MSKCC Ability to Offer OGM Testing
New York State Approval of Laboratory Heme Workflow Unlocks MSKCC Ability to Offer OGM Testing
Slide 23: Bionano Has Digitized the Human Chromosome for Clinical Application
Bionano Has Digitized the Human Chromosome for Clinical Application Optical Genome Mapping (OGM) is obsoleting the major laboratory standards of chromosomal visual analysis OGM consistently identifies previously undetected clinically relevant chromosomal structural variants Clinical publications fro
Slide 24: Thank you.
a Thank you.
Slide 25: Non-GAAP and Adjusted Financial Measures
Non-GAAP and Adjusted Financial Measures Note: Effective with the fiscal period ended March 31, 2026, the Company renamed certain of its non-GAAP financial measures. Measures previously reported as "non-GAAP gross margin," "non-GAAP operating expense," and other titles using "non-GAAP" are now prese
Slide 26: Adjusted Core Gross Margin
Adjusted Core Gross Margin qi Q2 Qs a4 qi Q2 Q3 a4 ql Q2 Q3 a4 Ql Q2 (In thousands) 2023 2023 2023 2023 2024 2024 2024 2024 2025 2025 2025 2025 2026 2026 Revenues: Total revenue $ 7,415 $ 8662 $ 9,318 $10,721 $ 8,769 $ 7,771 $ 6,073 $ 8,163 $ 6,457 $ 6,733 $ 7,367 $ 7,951 $ 6,687 $ 8,171 Less: Disco
Slide 27: Non-GAAP Operating Expenses
Non-GAAP Operating Expenses
Slide 28: Adjusted EBITDA
Adjusted EBITDA (In thousands) FY27 Revenue 33,813 $ 52,841 $ 75,232 $ 104,580 Cost of Revenue 17,171 24,718 32,733 43,615 Gross Margin $ 16,642 28,123 42,499 60,965 Gross Margin % 49.2% 53.2% 56.5% 58.3% Operating Expenses 45,782 46,264 52,004 57,737 Operating Income (Loss) (29,141) (18,140) (9,505